Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

Schlesinger: For advanced cSCC, immunotherapy has been a game-changer. The first immunotherapy drugs approved in the space were PD-1 inhibitors such as cemiplimab (Libtayo; Regeneron) and ...

Key combination for the treatment of Small Cell Lung Cancer MADRID and CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Vaginal lacerations during laparoscopic hysterectomy for endometrial cancer and local recurrence risk. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...

To investigate the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy versus anti–PD-1/PD-L1 monotherapy in advanced microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal ...

Cancer immunotherapy has transformed oncology, yet many patients fail to respond or eventually develop resistance.

(A) Presence of PD-1, its ligands PD-L1 and PD-L2, and the phosphatases SHP-1, SHP-2, and SHP-2-like (SHP-2L) in representative jawed vertebrates, including sharks, ray-finned fish, amphibians, and ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...

Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs' or the 'Company,' Stock Code: 9887.HK) announced on March 6, 2026 that the ...